Evaluating Immune Therapy, Duravalumab (MEDI4736) With Tremelimumab for Relapsed/Refractory Germ Cell Tumors

Clinical trial NCT03158064 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT03158064
Sponsor: Memorial Sloan Kettering Cancer Center
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Germ Cell Tumor Nonseminomatous Germ Cell Tumor Seminoma Germinomatous Germ Cell Tumor Dysgerminoma Pineal Germ Cell Tumor

Start date: 2017-05-15
Primary completion: 2026-11-01
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.